Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus

5 May 2025

Abstract excerpt

midges. The etiological agent, Bluetongue virus (BTV), can lead to severe economic losses due to reduced productivity and trade restrictions. Nowadays, classical vaccines based on inactivated viruses are used to control outbreaks but do not confer multiserotype protection, which reinforces the idea of pursuing research into developing strategies that enhance the immune response directed to conserved antigenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Disease Management and Epidemiology
Share to Vector-Borne Animal Diseases
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40391210
DOI: 10.3389/fimmu.2025.1566225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virusPMID 40391210Read ↗

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue VirusSemantic proximity Read ↗

Development and Evaluation of a Novel Vaccines against Bluetongue Virus Serotype 4 (BTV4)Semantic proximity Read ↗

Bluetongue virus: virology, pathogenesis and immunitySemantic proximity Read ↗

Vaccination With Recombinant Adenoviruses Expressing the Bluetongue Virus Subunits VP7 and VP2 Provides Protection Against Heterologous Virus ChallengeSemantic proximity Read ↗

Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccineSemantic proximity Read ↗

The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVASemantic proximity Read ↗

Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.Semantic proximity Read ↗

Bluetongue Viruses Based on Modified-Live Vaccine Serotype 6 with Exchanged Outer Shell Proteins Confer Full Protection in Sheep against Virulent BTV8Semantic proximity Read ↗

Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue VirusSemantic proximity Read ↗

Viral Vector Vaccines against Bluetongue VirusSemantic proximity Read ↗

Rapid Generation of Replication-Deficient Monovalent and Multivalent Vaccines for Bluetongue Virus: Protection against Virulent Virus Challenge in Cattle and SheepSemantic proximity Read ↗

Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challengeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.